|
1
|
Gruber UF: Asbestos-related benign disease
and cancer: Symptoms and treatment. Anticancer Drugs. 1:187–197.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jamrozik E, de Klerk N and Musk AW:
Asbestos-related disease. Intern Med J. 41:372–380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lazarus A, Massoumi A, Hostler J and
Hostler DC: Asbestos-related pleuropulmonary diseases: Benign and
malignant. Postgrad Med. 124:116–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Myers R: Asbestos-related pleural disease.
Curr Opin Pulm Med. 18:377–381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bibby AC and Maskell NA: Current
treatments and trials in malignant pleural mesothelioma. Clin
Respir J. 12:2161–2169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carbone M, Adusumilli PS, Alexander HR Jr,
Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E,
Galateau-Salle F, Jablons D, et al: Mesothelioma: Scientific clues
for prevention, diagnosis, and therapy. CA Cancer J Clin.
69:402–429. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sayan M, Eren MF, Gupta A, Ohri N, Kotek
A, Babalioglu I, Oskeroglu Kaplan S, Duran O, Derinalp Or O,
Cukurcayir F, et al: Current treatment strategies in malignant
pleural mesothelioma with a treatment algorithm. Adv Respir Med.
87:289–297. 2019. View Article : Google Scholar
|
|
8
|
Gray SG and Mutti L: Immunotherapy for
mesothelioma: A critical review of current clinical trials and
future perspectives. Transl Lung Cancer Res. 9(Suppl 1): S100–S119.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Gooijer CJ, Borm FJ, Scherpereel A and
Baas P: Immunotherapy in malignant pleural mesothelioma. Front
Oncol. 10:1872020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hotta K and Fujimoto N: Current evidence
and future perspectives of immune-checkpoint inhibitors in
unresectable malignant pleural mesothelioma. J Immunother Cancer.
8:e0004612020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hotta K, Fujimoto N, Kozuki T, Aoe K and
Kiura K: Nivolumab for the treatment of unresectable pleural
mesothelioma. Expert Opin Biol Ther. 20:109–114. 2020. View Article : Google Scholar
|
|
12
|
Kumagai-Takei N, Yamamoto S, Lee S, Maeda
M, Masuzzaki H, Sada N, Yu M, Yoshitome K, Nishimura Y and Otsuki
T: Inflammatory alteration of human T cells exposed continuously to
asbestos. Int J Mol Sci. 19:5042018. View Article : Google Scholar :
|
|
13
|
Matsuzaki H, Maeda M, Lee S, Nishimura Y,
Kumagai-Takei N, Hayashi H, Yamamoto S, Hatayama T, Kojima Y,
Tabata R, et al: Asbestos-induced cellular and molecular alteration
of immunocompetent cells and their relationship with chronic
inflammation and carcinogenesis. J Biomed Biotechnol.
2012:4926082012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishimura Y, Kumagai-Takei N, Matsuzaki H,
Lee S, Maeda M, Kishimoto T, Fukuoka K, Nakano T and Otsuki T:
Functional alteration of natural killer cells and cytotoxic T
lymphocytes upon asbestos exposure and in malignant mesothelioma
patients. BioMed Res Int. 2015:2384312015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishimura Y, Maeda M, Kumagai-Takei N, Lee
S, Matsuzaki H, Wada Y, Nishiike-Wada T, Iguchi H and Otsuki T:
Altered functions of alveolar macrophages and NK cells involved in
asbestos-related diseases. Environ Health Prev Med. 18:198–204.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumagai-Takei N, Lee S, Srinivas B,
Shimizu Y, Sada N, Yoshitome K, Ito T, Nishimura Y and Otsuki T:
The Effects of Asbestos Fibers on Human T Cells. Int J Mol Sci.
21:69872020. View Article : Google Scholar :
|
|
17
|
Maeda M, Nishimura Y, Hayashi H, Kumagai
N, Chen Y, Murakami S, Miura Y, Hiratsuka J, Kishimoto T and Otsuki
T: Decreased CXCR3 expression in CD4+ T cells exposed to
asbestos or derived from asbestos-exposed patients. Am J Respir
Cell Mol Biol. 45:795–803. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ying C, Maeda M, Nishimura Y,
Kumagai-Takei N, Hayashi H, Matsuzaki H, Lee S, Yoshitome K,
Yamamoto S, Hatayama T, et al: Enhancement of regulatory T
cell-like suppressive function in MT-2 by long-term and low-dose
exposure to asbestos. Toxicology. 338:86–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hyodoh F, Takata-Tomokuni A, Miura Y,
Sakaguchi H, Hatayama T, Hatada S, Katsuyama H, Matsuo Y and Otsuki
T: Inhibitory effects of anti-oxidants on apoptosis of a human
polyclonal T-cell line, MT-2, induced by an asbestos, chrysotile-A.
Scand J Immunol. 61:442–448. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miura Y, Nishimura Y, Katsuyama H, Maeda
M, Hayashi H, Dong M, Hyodoh F, Tomita M, Matsuo Y, Uesaka A, et
al: Involvement of IL-10 and Bcl-2 in resistance against an
asbestos-induced apoptosis of T cells. Apoptosis. 11:1825–1835.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyoshi I, Kubonishi I, Yoshimoto S and
Shiraishi Y: A T-cell line derived from normal human cord
leukocytes by co-culturing with human leukemic T-cells. Gan.
72:978–981. 1981.PubMed/NCBI
|
|
22
|
Miyoshi I, Kubonishi I, Yoshimoto S, Akagi
T, Ohtsuki Y, Shiraishi Y, Nagata K and Hinuma Y: Type C virus
particles in a cord T-cell line derived by co-cultivating normal
human cord leukocytes and human leukaemic T cells. Nature.
294:770–771. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamano R, Wu X, Wang Y, Oppenheim JJ and
Chen X: Characterization of MT-2 cells as a human regulatory T
cell-like cell line. Cell Mol Immunol. 12:780–782. 2015. View Article : Google Scholar
|
|
24
|
Chen S, Ishii N, Ine S, Ikeda S, Fujimura
T, Ndhlovu LC, Soroosh P, Tada K, Harigae H, Kameoka J, et al:
Regulatory T cell-like activity of Foxp3+ adult T cell
leukemia cells. Int Immunol. 18:269–277. 2006. View Article : Google Scholar
|
|
25
|
Yamamoto S, Lee S, Matsuzaki H,
Kumagai-Takei N, Yoshitome K, Sada N, Shimizu Y, Ito T, Nishimura Y
and Otsuki T: Enhanced expression of nicotinamide nucleotide
transhydrogenase (NNT) and its role in a human T cell line
continuously exposed to asbestos. Environ Int. 138:1056542020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maeda M, Nishimura Y, Hayashi H, Kumagai
N, Chen Y, Murakami S, Miura Y, Hiratsuka J, Kishimoto T and Otsuki
T: Reduction of CXC chemokine receptor 3 in an in vitro model of
continuous exposure to asbestos in a human T-cell line, MT-2. Am J
Respir Cell Mol Biol. 45:470–479. 2011. View Article : Google Scholar
|
|
27
|
Maeda M, Chen Y, Lee S, Kumagai-Takei N,
Yoshitome K, Matsuzaki H, Yamamoto S, Hatayama T, Ikeda M,
Nishimura Y, et al: Induction of IL-17 production from human
peripheral blood CD4+ cells by asbestos exposure. Int J Oncol.
50:2024–2032. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maeda M, Miura Y, Nishimura Y, Murakami S,
Hayashi H, Kumagai N, Hatayama T, Katoh M, Miyahara N, Yamamoto S,
et al: Immunological changes in mesothelioma patients and their
experimental detection. Clin Med Circ Respirat Pulm Med. 2:11–17.
2008.PubMed/NCBI
|
|
29
|
Pass HI, Alimi M, Carbone M, Yang H and
Goparaju CM: Mesothelioma biomarkers: Discovery in search of
validation. Thorac Surg Clin. 30:395–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Furuya S, Chimed-Ochir O, Takahashi K,
David A and Takala J: Global asbestos disaster. Int J Environ Res
Public Health. 15:10002018. View Article : Google Scholar :
|
|
31
|
Richards AB, Krakowka S, Dexter LB, Schmid
H, Wolterbeek AP, Waalkens-Berendsen DH, Shigoyuki A and Kurimoto
M: Trehalose: A review of properties, history of use and human
tolerance, and results of multiple safety studies. Food Chem
Toxicol. 40:871–898. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Teramoto N, Sachinvala ND and Shibata M:
Trehalose and trehalose-based polymers for environmentally benign,
biocompatible and bioactive materials. Molecules. 13:1773–1816.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roohbakhsh A, Parhiz H, Soltani F, Rezaee
R and Iranshahi M: Neuropharmacological properties and
pharmacokinetics of the citrus flavonoids hesperidin and hesperetin
- a mini-review. Life Sci. 113:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Parhiz H, Roohbakhsh A, Soltani F, Rezaee
R and Iranshahi M: Antioxidant and anti-inflammatory properties of
the citrus flavonoids hesperidin and hesperetin: An updated review
of their molecular mechanisms and experimental models. Phytother
Res. 29:323–331. 2015. View Article : Google Scholar
|
|
35
|
Higashiyama T: Novel functions and
applications of trehalose. Pure Appl Chem. 74:1263–1269. 2002.
View Article : Google Scholar
|
|
36
|
Lee HJ, Yoon YS and Lee SJ: Mechanism of
neuroprotection by trehalose: Controversy surrounding autophagy
induction. Cell Death Dis. 9:7122018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khalifeh M, Barreto GE and Sahebkar A:
Trehalose as a promising therapeutic candidate for the treatment of
Parkinson' s disease. Br J Pharmacol. 176:1173–1189. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y and DeBosch BJ: Using trehalose to
prevent and treat metabolic function: Effectiveness and mechanisms.
Curr Opin Clin Nutr Metab Care. 22:303–310. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iranshahi M, Rezaee R, Parhiz H,
Roohbakhsh A and Soltani F: Protective effects of flavonoids
against microbes and toxins: The cases of hesperidin and
hesperetin. Life Sci. 137:125–132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tejada S, Pinya S, Martorell M, Capó X,
Tur JA, Pons A and Sureda A: Potential anti-inflammatory effects of
hesperidin from the genus citrus. Curr Med Chem. 25:4929–4945.
2018. View Article : Google Scholar
|
|
41
|
Chikara S, Nagaprashantha LD, Singhal J,
Horne D, Awasthi S and Singhal SS: Oxidative stress and dietary
phytochemicals: Role in cancer chemoprevention and treatment.
Cancer Lett. 413:122–134. 2018. View Article : Google Scholar
|
|
42
|
Miwa Y, Yamada M, Sunayama T, Mitsuzumi H,
Tsuzaki Y, Chaen H, Mishima Y and Kibata M: Effects of glucosyl
hesperidin on serum lipids in hyperlipidemic subjects: Preferential
reduction in elevated serum triglyceride level. J Nutr Sci
Vitaminol (Tokyo). 50:211–218. 2004. View Article : Google Scholar
|
|
43
|
Yamada M, Tanabe F, Arai N, Mitsuzumi H,
Miwa Y, Kubota M, Chaen H and Kibata M: Bioavailability of glucosyl
hesperidin in rats. Biosci Biotechnol Biochem. 70:1386–1394. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
45
|
Wong WF, Kohu K, Chiba T, Sato T and
Satake M: Interplay of transcription factors in T-cell
differentiation and function: The role of Runx. Immunology.
132:157–164. 2011. View Article : Google Scholar :
|
|
46
|
Kufer P, Zettl F, Borschert K, Lutterbüse
R, Kischel R and Riethmüller G: Minimal costimulatory requirements
for T cell priming and TH1 differentiation: Activation of naive
human T lymphocytes by tumor cells armed with bifunctional antibody
constructs. Cancer Immun. 1:102001.
|
|
47
|
Rabinovich GA, Gabrilovich D and Sotomayor
EM: Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar
|
|
48
|
Byun S, Lee E and Lee KW: Therapeutic
implications of autophagy inducers in immunological disorders,
infection, and cancer. Int J Mol Sci. 18:19592017. View Article : Google Scholar :
|
|
49
|
Casarejos MJ, Solano RM, Gómez A, Perucho
J, de Yébenes JG and Mena MA: The accumulation of neurotoxic
proteins, induced by proteasome inhibition, is reverted by
trehalose, an enhancer of autophagy, in human neuroblastoma cells.
Neurochem Int. 58:512–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Q and Ren J: mTOR-Independent
autophagy inducer trehalose rescues against insulin
resistance-induced myocardial contractile anomalies: Role of p38
MAPK and Foxo1. Pharmacol Res. 111:357–373. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Belzile JP, Sabalza M, Craig M, Clark AE,
Morello CS and Spector DH: Trehalose, an mTOR-independent inducer
of autophagy, inhibits human cytomegalovirus infection in multiple
cell types. J Virol. 90:1259–1277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wu Q, Jiang D, Huang C, van Dyk LF, Li L
and Chu HW: Trehalose-mediated autophagy impairs the anti-viral
function of human primary airway epithelial cells. PLoS One.
10:e01245242015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Monforte MT, Trovato A, Kirjavainen S,
Forestieri AM, Galati EM and Lo Curto RB: Biological effects of
hesperidin, a Citrus flavonoid. (note II): Hypolipidemic activity
on experimental hypercholesterolemia in rat. Farmaco. 50:595–599.
1995.PubMed/NCBI
|
|
54
|
Yamamoto M, Suzuki A, Jokura H, Yamamoto N
and Hase T: Glucosyl hesperidin prevents endothelial dysfunction
and oxidative stress in spontaneously hypertensive rats. Nutrition.
24:470–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Martínez MC, Fernandez SP, Loscalzo LM,
Wasowski C, Paladini AC, Marder M, Medina JH and Viola H:
Hesperidin, a flavonoid glycoside with sedative effect, decreases
brain pERK1/2 levels in mice. Pharmacol Biochem Behav. 92:291–296.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Loscalzo LM, Wasowski C, Paladini AC and
Marder M: Opioid receptors are involved in the sedative and
antinociceptive effects of hesperidin as well as in its
potentiation with benzodiazepines. Eur J Pharmacol. 580:306–313.
2008. View Article : Google Scholar
|
|
57
|
Bellavite P and Donzelli A: Hesperidin and
SARS-CoV-2: New light on the healthy function of citrus fruits.
Antioxidants. 9:7422020. View Article : Google Scholar :
|
|
58
|
Ding Z, Sun G and Zhu Z: Hesperidin
attenuates influenza A virus (H1N1) induced lung injury in rats
through its anti-inflammatory effect. Antivir Ther. 23:611–615.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Maeda M, Chen Y, Hayashi H, Kumagai-Takei
N, Matsuzaki H, Lee S, Nishimura Y and Otsuki T: Chronic exposure
to asbestos enhances TGF-β1 production in the human adult T cell
leukemia virus-immortalized T cell line MT-2. Int J Oncol.
45:2522–2532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Maeda M, Matsuzaki H, Yamamoto S, Lee S,
Kumagai-Takei N, Yoshitome K, Min Y, Sada N, Nishimura Y and Otsuki
T: Aberrant expression of FoxP3 in a human T cell line possessing
regulatory T cell like function and exposed continuously to
asbestos fibers. Oncol Rep. 40:748–758. 2018.PubMed/NCBI
|
